| CAS ID: | 59865-13-3 |
| Molecular Formula: | C62H111N11O12 |
| Molecular Weight: | 1202.6 g/mol |
| Monoisotopic Mass: | 1201.841 g/mol |
| Class: | Peptide |
| Natural Product: | No |
| Other Names: | RESTASIS | 27-400 | CAPSORIN | OPTIMMUNE | GENGRAF | DEXIMUNE | CYCLOSPORINE | CICLOSPORIN | SANDIMMUNE | NEORAL | IKERVIS | VANQUORAL | CAPIMUNE | CYCLOSPORIN A | SANGCYA | SANDIMMUN | RESTASIS MULTIDOSE |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1 | See All |
| InChI Key: | PMATZTZNYRCHOR-CGLBZJNRSA-N | |
| Smiles: | CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C | See All |
| Molfile: | Download |
Reference Record 1
| PubMed ID | 17262945 | Target ID | |
| Uniprot ID | Name | ||
| Model | rat | Fibrosis Disease | Cardiac fibrosis |
| Process I | |||
| Process II | fibroblasts proliferation | ||
| Process III | prevenet collagen deposition | ||
| Mechanism | |||
Reference Record 2
Trial Record 1
| ClinicalTrial ID | NCT01079143 | Disease | Renal fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | March 2, 2010 | Last Verified | March 18, 2014 |
| Sponsor | Novartis Pharmaceuticals | ||
Trial Record 2
| ClinicalTrial ID | NCT00493194 | Disease | Renal fibrosis |
| Phase | Phase 4 | Status | Unknown |
| First Received | June 28, 2007 | Last Verified | November 26, 2008 |
| Sponsor | University Hospital, Antwerp | ||
Trial Record 3
| ClinicalTrial ID | NCT00260208 | Disease | Liver fibrosis |
| Phase | Phase 4 | Status | Terminated |
| First Received | December 1, 2005 | Last Verified | December 6, 2011 |
| Sponsor | Novartis Pharmaceuticals | ||
Trial Record 4
| ClinicalTrial ID | NCT03192657 | Disease | Pulmonary fibrosis |
| Phase | Phase 2 | Status | Not yet recruiting |
| First Received | June 20, 2017 | Last Verified | June 20, 2017 |
| Sponsor | RenJi Hospital | ||
Trial Record 5
| ClinicalTrial ID | NCT00006054 | Disease | Fibrosis |
| Phase | Not Applicable | Status | Terminated |
| First Received | July 6, 2000 | Last Verified | October 15, 2009 |
| Sponsor | Fairview University Medical Center | ||
Trial Record 6
| ClinicalTrial ID | NCT00637143 | Disease | Renal fibrosis |
| Phase | Phase 4 | Status | Completed |
| First Received | March 17, 2008 | Last Verified | February 16, 2017 |
| Sponsor | Astellas Pharma Inc | ||
Trial Record 7
| ClinicalTrial ID | NCT01987791 | Disease | Liver fibrosis |
| Phase | Status | Unknown | |
| First Received | November 19, 2013 | Last Verified | November 19, 2013 |
| Sponsor | Peking University People's Hospital | ||